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Abstract: The aim of this study was to evaluate the expression of COX-2 and Bcl-2 in primary fallopian tube
carcinoma (PFTC), as well as their correlations with clinicopathologic features. We studied a cohort of 33 pa-
tients with a pathological diagnosis of PFTC. Thirty normal tubal tissues used for controls were obtained from
patients diagnosed with uterine myomas. Expression analysis for COX-2 and Bcl-2 was performed using the
immunohistochemical technique. The rate of preoperative diagnosis was 18.2%. With a median survival of 61.0
months (95% CI: 43.2 to 78.8 months), the estimated five-year overall survival rate in the 33 patients was 39.0%.
Increased expression of COX-2 and Bcl-2 was observed in tumor specimens compared to normal controls
(p = 0.026; p = 0.003). The expression rate of COX-2 in node-positive tumors was significantly higher than that
of node-negative tumors (p = 0.024). Moreover, the expression rate of COX-2 was statistically significantly
higher in patients with infiltration through the serosa (p = 0.019). Positive significant associations were ob-
served between Bcl-2 staining index and FIGO stage (p = 0.015), and between Bcl-2 staining and lymph node
metastasis (p = 0.010). There was a significant correlation between COX-2 expression and Bcl-2 staining index
(r = 0.517, p = 0.002). We conclude that COX-2 and Bcl-2 may potentially be useful prognostic markers for
PFTC. The exact molecular mechanism for correlations between COX-2 and Bcl-2 remains to be elucidated.
(Folia Histochemica et Cytobiologica 2011, Vol. 49, No. 3, 389–397)
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Introduction
Primary fallopian tube carcinoma (PFTC) is one of
the rarest malignant tumors of the female genital tract,
although the incidence of PFTC is gradually increas-
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ing [1]. Tube malignancy mainly affects postmeno-
pausal women in the fifth and sixth decades of life,
with symptoms such as abdominal pain, vaginal bleed-
ing, abnormal watery discharge and pelvic mass [2].
In addition to the surgical principle of optimal cy-
toreduction used for patients with ovarian carcino-
ma, the adoption of chemotherapeutic agents has also
been advocated for patients with PFTC. A combina-
tion of paclitaxel and platinum-based therapy has been
recommended as the standard chemotherapy regimen
for PFTC patients [3]. PFTC has rarely been studied,
and only a few reports with fairly small numbers have
investigated the molecular events associated with this
cancer [4, 5]. Analyses of potential molecular media-
tors would be helpful to guide treatment and to eluci-
date the mechanisms of disease pathogenesis.
The cyclooxygenase (COX) genes encode for the
rate-limiting enzyme involved in the conversion of
arachidonic acid to H2-prostaglandin [6]. Two COX
genes, COX-1 and COX-2, have been identified.
COX-1 is constitutively expressed. COX-2 gene ex-
pression has been demonstrated to increase in re-
sponse to cytokines, mitogens, and growth factors [7].
High expression of COX-2 in a wide variety of solid
epithelial tumors also favors the growth of malignant
cells by inhibition of apoptosis and the promotion of
angiogenesis [8]. Some studies have found a high cor-
relation between the expression of this enzyme and
cancer growth or prognosis [9, 10].
The Bcl-2 family is implicated in the regulation of
apoptosis. The Bcl-2 family, with its antiapoptotic
subgroups (Bcl-2, Bcl-xl, Mcl-1, and A1) and its death-
-promoting subgroups (Bax, Bcl-xs, Bak, Bad, and Bik)
plays a central role in the regulation of cell death [11].
The Bcl-2 gene encodes a 26-kDa protein located in
the mitochondrial inner membrane and cell cytosol.
Bcl-2 protein acts as an inhibitor of apoptosis; it con-
tributes to cancer pathogenesis and may be involved
in resistance to cancer treatment [12]. The expres-
sion of Bcl-2 in a variety of tumor types has prompt-
ed intense research directed toward the role of this
molecule in the pathogenesis of tumors.
So far as we know, no study has investigated the
expression of COX-2 and Bcl-2 protein in PFTC.
Thus, the aim of the current study was to investigate
the expression of COX-2 and Bcl-2 and to correlate
their expressions with the clinicopathologic features
in PFTC. The relationship between Cox-2 and Bcl-2
protein expression was also evaluated.
Material and methods
Clinical data and tumor specimen acquisition. A total of
33 cases were diagnosed with PFTC. All were treated in
one of the following hospitals: the First Affiliated Hospital
of Anhui Medical University, Anhui Provincial Hospital,
and the First People’s Hospital of Hefei, Anhui between
January 1995 and October 2009. They were all submitted to
surgery as the primary treatment. None of these patients
received preoperative chemotherapy, radiotherapy or im-
munotherapy. Clinical information and paraffin blocks were
available for all the patients. Data on clinical parameters,
including age, signs, symptoms, preoperative examination,
preoperative diagnosis, treatment and follow-up informa-
tion were gathered retrospectively from patient records. The
variables studied in the pathology review were: tumor size,
location, histological type, grading, depth of tubal wall in-
filtration, lymph node status and vascular space invasion.
The histological specimens were all sent to the First Affili-
ated Hospital of Anhui Medical University, where the spec-
imens were re-assessed by two independent pathologists.
All cases were staged retrospectively according to the mod-
ified International Federation of Gynecology and Obstet-
rics (FIGO) staging system. The diagnostic criteria for PFTC
proposed by Hu et al. and modified by Sedlis was applied
[13]. Optimal cytoreduction was defined as residual tumor
no greater than 1 cm in diameter at the conclusion of sur-
gery. The 1 cm cut-off was used as the threshold in order to
homogeneously assess patients diagnosed during different
periods of time in this long retrospective study [3].
For patients with measurable disease after primary cy-
toreductive surgery, overall tumor response was defined
using the modified Response Evaluation Criteria In Solid
Tumors (RECIST), which also requires that complete re-
sponse (CR) includes normalization of CA-125 levels. Non-
-measurable disease included cystic lesions and ascites. Pel-
vic and abdominal CT scan and/or MRI and chest X-ray
and/or chest CT scan were repeated after the third and the
sixth treatment courses.
Thirty normal tubal tissues used for controls were ob-
tained from patients diagnosed with uterine myomas. They
had hysterectomy and bilateral salpingo-oophorectomy
performed in the First Affiliated Hospital of Anhui Med-
ical University between January 2004 and January 2007.
The specimens were also re-assessed by two independent
pathologists, excluded for tumor or inflammation of the
fallopian tubes.
Histology. The formalin-fixed, paraffin-embedded samples
were sectioned at 4 μm and stained with hematoxylin and
eosin. The histological diagnosis was re-examined by two
independent pathologists. Moreover, the most representa-
tive blocks were selected to be cut into new 4 μm-thick sec-
tions for immunohistochemical study.
Immunohistochemical staining. Immunohistochemical
staining was performed by a peroxidase-labelled streptavi-
din-biotin method. Sections were dewaxed and antigen re-
trieval was achieved by steaming the slides for 20 minutes
in retrieval solution. Endogenous peroxidase activity was
391COX-2 and Bcl-2 in primary fallopian tube carcinoma
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2011
10.5603/FHC.2011.0055
www.fhc.viamedica.pl
blocked by incubation in 3% hydrogen peroxide solution.
The antibodies used were a polyclonal rabbit antibody
against COX-2 protein (clone sc-7951; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) in a 1:25 dilution at room
temperature for one hour, and a monoclonal mouse anti-
body against Bcl-2 protein (clone sc-7382; Santa Cruz Bio-
technology, Santa Cruz, CA, USA) in a 1:100 dilution at
room temperature for one hour. After washing three times
with phosphate buffered saline (PBS), sections were incu-
bated with biotinylated goat anti-rabbit/anti-mouse immu-
noglobulin (Zymed Laboratories, USA) for ten minutes.
They were then washed three times with PBS, treated with
streptavidin–peroxidase reagent (Zymed Laboratories, San
Francisco, CA, USA) for ten minutes, and then washed again
with PBS three times. Finally, specimens were incubated in
diaminobenzidine (DAB) for five minutes, followed by be-
ing counterstained with hematoxylin for one minute, rinsed
twice in distilled water, and dehydrated with ethanol followed
by xylene. Tissue from a colon cancer known to overexpress
COX-2, and tissue from a tonsil specimen with a known ex-
pression of Bcl-2, served as positive controls. The primary
antibody was replaced with PBS as a negative control.
Immunohistochemical evaluation. Semiquantitative evalu-
ation of the immunohistochemical results was performed by
two independent observers blinded to patient status. The IHC
quantification for COX-2 and Bcl-2 followed previous pub-
lished criteria based on intensity and percentage taken togeth-
er. Firstly, the percentage of tumoral cells was scored as 0: <
< 5%, 1: 5–25%, 2: 26–50%, 3: 51–75% or 4: > 75% of positive
cells respectively. Secondly, the intensity was validated as 0: no
reaction, 1: weak reactivity, 2: moderate or 3: intense. With
these two molecules, a combined score was subsequently de-
termined by multiplying the scores of intensity and percentage
from different tumoral areas. The cytoplasmic positivity for
COX-2 and Bcl-2 was graded as follows: negative (scored 0–1),
+1 (scored 2–3), +2 (scored 4–6), +3 (scored > 6). The ex-
pression of proteins was classified into positive (Grade +1~
~ +3) and negative (Grade 0) expressions [14, 15].
Statistical analysis. Overall survival (OS) curve was plotted,
and median survival time was estimated using the Kaplan–
–Meier method [16]. OS was defined as the time from the day
of operation to the time of death; data on survivors were cen-
sored at the last follow-up. Median overall survival was de-
fined as the time-point where the Kaplan–Meier curve crossed
the horizontal line at 50% survival probability. Distributions
for immunostaining of molecules between PFTC and nor-
mal controls were compared and analyzed by the Chi-square
test. Associations between immunohistochemical parameters
and clinicopathologic parameters were determined using the
Fisher’s exact test. The Pearson Chi-square test was used to
assess the relation between COX-2 and Bcl-2 expression;
p values < 0.05 was regarded as statistically significant in two
tailed tests, using SPSS for Windows 13.0 software.
Results
Patients’ characteristics
A total of 33 patients with a pathological diagnosis of
PFTC were collected in this retrospective analysis. The
median age at diagnosis was 55 years (range 40–73).
Clinicopathologic features of patients with PFTC are
listed in Table 1.
One patient (3%) was nulliparous, eight patients
(24%) had experienced one live birth, and 24 patients
(73%) two or more live births. At the time of diagno-
sis, 22 patients (66.7%) were postmenopausal. The
commonest signs and symptoms were: abnormal wa-
tery discharge (54.5%), abdominal pain (30.3%), ab-
normal vaginal bleeding (24.2%) and a palpable pel-
vic and/or abdominal mass (18.2%). The tumor was
Table 1. Patients’ characteristics*
Variables No. of patients (%)
Age, median, range 55 (40–73)
Menopausal
Yes 22 (66.7)
No 11 (33.3)
FIGO stage
 I 6 (18.2)
II 10 (30.3)
III 15 (45.5)
IV 2 (6.0)
Histological type
Serous adenocarcinoma 19 (57.6)
Papillary adenocarcinoma 4 (12.0)
Tubal adenocarcinoma 5 (15.2)
Adenocarcinoma NOS 5 (15.2)
Grade
G1 5 (15.1)
G2 16 (48.5)
G3 12 (36.4)
Depth of tubal wall infiltration
Intramucosal or submucosa/muscularis 24 (72.7)
Through serosa 9 (27.3)
Location
Left 16 (48.5)
Right 15 (45.5)
Bilateral 2 (6.0)
Residual tumor
£ 1 cm 23 (69.7)
> 1 cm 10 (30.3)
Lymph node metastasis
No 22 (66.7)
Yes 11 (33.3)
Chemotherapy agents
TP (paclitaxel + cisplatin/carboplatin) 16 (48.5)
CAP (cyclophosphamide + epirubicin +
+ cisplatin/carboplatin) 17 (51.5)
*FIGO — International Federation of Gynecology and Obstetrics;
NOS — not otherwise specified
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an incidental finding at laparotomy in two patients
(6.1%) who underwent surgery for nonmalignant in-
dications. Despite this, a preoperative diagnosis of
PFTC was made only in six patients (18.2%). Among
these patients, it was demonstrated that transvaginal
ultrasound examination with color Doppler can de-
tect areas of neovascularization within the fallopian
tube, and thus aid in the preoperative diagnosis of
PFTC. The majority of patients were of serous his-
tology, and in 12 patients (36.4%) the tumors were
poorly differentiated. CA-125 was measured preop-
eratively in all patients and was found to be elevated
(> 35 U/ml) in 30 of these patients (range, 8.84–1,000
U/ml; median, 162.2 U/ml).
For patients with early-stage disease, the surgical
procedure included a total abdominal hysterectomy,
bilateral salpingo-oophorectomy, omentectomy, and
routine pelvic and para-aortic lymph node sampling
of lymph nodes that were visible or palpable after
opening of the visceral peritoneum. For patients with
advanced disease, aggressive cytoreductive surgery
with removal of as much tumor as possible is war-
ranted. Positive lymph nodes were found in 11 of 25
patients with palpable lymph nodes removed at pri-
mary surgery. Suboptimal debulking surgery with re-
sidual disease > 1 cm was recorded in ten (30.3%)
cases. Adjuvant chemotherapy with platinum-contain-
ing regimen was offered to all the patients involved
in our study. Sixteen (48.5%) patients received a com-
bination of paclitaxel and platinum, whereas the oth-
er 17 patients (51.5%) were treated with a regimen
of platinum-epirubicin-cyclophosphamide combina-
tions. Objective response was assessed in ten (30.3%)
patients with measurable disease. One of these pa-
tients had a complete clinical response (CR), three
had partial response (PR), two had stable disease
(SD) and four had progressive disease (PD), induc-
ing an overall response rate (CR + PR) of 40.0%.
Clinical benefit (CR + PR + SD) was observed in
60% of patients with measurable disease.
At the time of analysis, only one patient was lost
to follow-up, 12 (36.4%) patients had relapsed and
eight (24.2%) had died. With a median follow-up of
25 months (range: 4–119 months), the median over-
all survival was 61 months (95% CI: 43.2 to 78.8
months) for the entire population. The one, three,
and five year overall survival rates were 88%, 68%,
and 39%, respectively. Figure 1 demonstrates the
overall survival curve by Kaplan–Meier method for
the 33 patients with PFTC.
Immunohistochemical results
Expression of COX-2 and Bcl-2 in PFTC
and normal fallopian tube tissues
Table 2 summarizes the results from the immunohis-
tochemical analysis of 33 tumor specimens and 30
normal controls. The expression of COX-2 and Bcl-2
was detected as diffuse brown cytoplasmic or mem-
branous reaction. The expression analysis of COX-2
revealed that in 14 of 33 (42.4%) tumor tissues, COX-2
staining was positive (Figure 2A) whereas in five of
Table 2. Expression of COX-2 and Bcl-2 in PFTC and normal fallopian tube*
          Variables COX-2 expression Bcl-2 expression
Negative Positive Expression Negative Positive Expression
rate (%) rate (%)
PFTC 19 14 42.4 17 16 48.5
(n = 33)
Normal tube 25 5 16.7 26 4 13.3
(n = 30)
c2 4.95 8.96
p 0.026 0.003
*PFTC — primary fallopian tube carcinoma
Figure 1. Overall survival curve for the entire population
of the study
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30 (16.7%) normal tissues, cytoplasmic expression was
recorded (Figure 2B). There was a significant differ-
ence between the expression rate in tumor tissues and
in normal tissues (c2 = 4.95; p = 0.026). Positive ex-
pression of Bcl-2 was observed in 16 of 33 (48.5%)
tumor tissues (Figure 2C) but in only four of 30
(13.3%) normal tissues (Figure 2D). The difference
between Bcl-2 expression rate in tumor tissues and
normal tissues was also statistically significant (c2 =
= 8.96; p = 0.003).
COX-2 and Bcl-2 protein expression in relation to
classification of clinicopathologic features
Clinicopathologic features including menopausal,
FIGO stage, histological type, grade, depth of tubal
wall infiltration and lymph node metastasis grouping
of the cancers in relation to COX-2 and Bcl-2 expres-
sion are shown in Table 3. Expression of COX-2 was
significantly correlated with depth of tubal wall infil-
tration in PFTC (p = 0.019). We also found the ex-
pression rate of COX-2 in tumors with lymph node
metastasis was significantly higher than that of node-
-negative tumors (72.7% vs. 27.3%, p = 0.024). How-
ever, there were no significant associations between
COX-2 expression and other parameters including
menopausal, FIGO stage, histological type and grade.
As far as Bcl-2 staining is concerned, a statistically
significant higher expression rate of Bcl-2 was found
in cases with lymph node metastasis than in cases with-
out lymph node metastasis (81.8% vs. 31.8%,
Figure 2. A. Diffuse and marked membranous and cytoplasmic positivity for COX-2 in primary fallopian tube carcinoma
(Streptavidin-peroxidase × 400). B. Membranous positivity for COX-2 in normal fallopian tube tissue (Streptavidin-
-peroxidase × 400). C. Intense membranous positivity for Bcl-2 in primary fallopian tube carcinoma (Streptavidin-
-peroxidase × 400). D. Membranous positivity for Bcl-2 in normal fallopian tube tissue (Streptavidin-peroxidase × 400)
A B
C D
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p = 0.010). In addition, the expression rate of Bcl-2
was higher in cases staged III and IV with respect to
cases staged I and II (70.6% vs. 25.0%, p = 0.015).
There was no significant difference in expression rates
of Bcl-2 in patients among menopausal, histologic type,
grade and depth of tubal wall infiltration.
Correlation between COX-2 expression
and Bcl-2 expression
Table 4 summarizes the correlation between the im-
munohistochemical results of COX-2 and Bcl-2 in
PFTC. Using the Pearson Chi-square test, a positive
significant correlation was found between COX-2 ex-
pression and Bcl-2 expression (r = 0.517, p = 0.002).
Discussion
In the current study, we have performed a retrospec-
tive analysis of 33 PFTC patients in three different
hospitals. Furthermore, we have investigated the ex-
pression of COX-2 and Bcl-2 and correlated their ex-
pressions with the clinicopathologic features in PFTC.
PFTC most frequently occurs in the fourth, fifth
and sixth decades of life, with a median age of occur-
rence of 55 years (range, 17–88 years) [1]. High pari-
ty and a history of pregnancy have been reported to
decrease the PFTC risk significantly [2]. Unlike these
reports, our study showed that only one patient had
a history of infertility. It may be that the protective and
risk factors of PFTC vary by race. The rate of preop-
erative diagnosis is in the range of 0–10% in the liter-
ature [17]. However, preoperative diagnosis of PFTC
was made in six patients (18.2%) in our cohort. Most
of the patient characteristics described in this mate-
rial were quite comparable to those reported in the
literature. However, the five-year survival rate of 39%
was somewhat lower in the present series than in most
reports. In a large population-based registry study of
151 PFTC patients, the reported five-year survival rate
was 44%, and the median survival time was 52 months
Table 3. Relations between COX-2 expression and clinicopathologic features in PFTC*
           Variables n COX-2 expression Bcl-2 expression
Negative Positive Expression p Negative Positive Expression p
rate (%) rate (%)
Menopausal
Yes 22 13 9 40.9 1.000 10 12 54.5 0.465
No 11 6 5 45.5 7 4 36.4
FIGO stage
I–II 16 11 5 31.3 0.296 12 4 25.0 0.015
III–IV 17 8 9 52.9 5 12 70.6
Histological type
Serous 19 9 10 52.6 0.286 8 11 57.9 0.296
Other types 14 10 4 28.6 9 5 35.7
Grade
G1, G2 21 13 8 38.1 0.716 12 9 42.9 0.200
G3 12 6 6 50.0 5 7 58.3
Depth of tubal
wall infiltration
Intramucosal or 24 17 7 29.2 0.019 14 10 41.7 0.259
submucosa/muscularis
Through serosa 9 2 7 77.8 3 6 66.7
Lymph node metastasis
No 22 16 6 27.3 0.024 15 7 31.8 0.010
Yes 11 3 8 72.7 2 9 81.8
*FIGO — International Federation of Gynecology and Obstetrics; PFTC — primary fallopian tube carcinoma
Table 4. Correlation between COX-2 and Bcl-2 expression in primary fallopian tube carcinoma
COX-2                                          Bcl-2
r p
Negative Positive
Negative 14 5
0.517 0.002
Positive 3 11
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[13]. Gadducci et al. [18] reported that for the whole
series the five-year survival rate was 57%. It is likely
that the shorter follow-up time may partly account
for the relatively lower survival rate in our study.
Additionally, 51.6% of the patients were in an ad-
vanced stage of their disease. It is known that stage is
an important prognostic factor for outcome [1, 13].
COX-2 is normally undetectable in most tissues
and can be induced by a number of stimuli, including
cytokines such as IL-1, interferon-g and tumor ne-
crosis factor [19]. In the current study, we showed for
the first time that increased expression of COX-2 in
vivo was accompanied by increased expression of Bcl-2
protein in PFTC compared to normal fallopian tube
tissues. This result suggests that COX-2 and Bcl-2 may
both play important roles in promoting tumorigene-
sis. Moreover, we found significant correlations be-
tween COX-2 expression and depth of tubal wall in-
filtration and lymph node metastasis in our study,
a finding that was compatible with previous reports
on other organs [12, 20]. Therefore, COX-2 might
have played a role in activating the metastatic poten-
tial of tumor cells in our patients.
Chen et al. [21] reported a significantly higher ex-
pression of COX-2 in endometrial carcinoma than in
normal endometrium tissue and COX-2 expression
was related to the histological grade. A study from
Thailand provided evidence that COX-2 was overex-
pressed in the colorectal tumor tissues and their pres-
ence was significantly correlated with poor differen-
tiation [22]. However, in the present study, we were
unable to identify any correlation between COX-2
staining and histological grade. To the best of our
knowledge, there is no generally accepted grading
system for PFTC, mainly because the same criteria
are not applicable to all histologic types. Consistent
with our notion, Ohno et al. [20] reported that COX-2
mRNA expression in gastric carcinoma tissue is cor-
related closely with depth of invasion. Another simi-
lar finding suggested that COX-2 was a good predic-
tor for lymph node metastasis in mucoepidermoid
carcinoma [12]. Compelling evidence suggests that
COX-2 might enhance the metastatic potential as well
as tumorigenicity and might be involved in the pro-
gression of some tumors.
COX-2 contributes to tumorigenesis through sev-
eral mechanisms. These include an increase in prolif-
eration, reduction in apoptosis, promotion of angio-
genesis, modulation in inflammation and immune
function, decrease in E-cadherin expression, and stim-
ulation in the invasive/metastatic potential [23]. Stud-
ies have demonstrated the effects of non-steroidal
anti-inflammatory drugs (NSAIDs) in the prevention
of human cancers. Recent progress in the treatment
and prevention of cancers of the lung, breast, esoph-
agus, colon, bladder and prostate with NSAIDs, es-
pecially COX-2 inhibitors, has increased our under-
standing of COX-2 inhibition in both cancer treat-
ment and prevention [24, 25]. Previous studies from
our laboratory have suggested the effects of paeonol
in the prevention of human cancers in vitro and in
vivo by inducing apoptosis. Thus, the inhibition of
COX-2 enzymatic activity in controlling neoplastic cell
proliferation is the possible mechanism [26–28].
Therefore, these studies suggest the potential use of
COX-2 inhibitors combined with other chemothera-
py drugs or irradiation in the treatment of PFTC.
This study, the first to assess the clinical useful-
ness of Bcl-2 expression in PFTC, showed that Bcl-2
expression rate differed according to FIGO stage and
was significantly higher in node-positive tumors com-
pared to node-negative tumors. These findings indi-
cate that Bcl-2 may be a critical factor affecting the
tumorigenesis and progression of PFTC, as well as
an indicator of biologic behavior. The role of Bcl-2 in
the current results parallels those of other studies.
Shimizu et al. [10] found that Bcl-2 gene expression
increased during progression from normal tissue to
Barrett’s associated adenocarcinoma. Another study
revealed that the expression of Bcl-2 was significant-
ly higher in malignant than in benign tumors, and was
higher in serous than in mucinous borderline ovarian
tumors [29]. Bcl-2 has functions in tissue differentia-
tion and development, apart from prolonged cell
lifespan by blocking apoptosis. Reducing the capaci-
ty of apoptotic cell turnover could be an important
step in the development of neoplasia [30].
Our findings indicated that COX-2 overexpression
in tumor tissues was associated with Bcl-2 overexpres-
sion. To date, COX-2 has been determined to con-
tribute to tumorigenesis and the malignant pheno-
type of tumor cells via the inhibition of apoptosis, in-
creased angiogenesis and invasiveness. Growing evi-
dence indicates that induction of COX-2 correlates
with increased Bcl-2 expression. Tjiu et al. [31] found
that Mcl-1 and Bcl-2, both members of the Bcl-2 fam-
ily, were significantly upregulated in COX-2-overex-
pressing human basal cell carcinoma cells, whereas
other Bcl-2 members were not. This implicated Mcl-1
and Bcl-2 in COX-2-mediated antiapoptotic effects.
Sakamoto et al. [32] reported that COX-2 regulated
the degree of apoptosis by modulating Bcl-2 protein
in pleomorphic adenoma and mucoepidermoid car-
cinoma of the parotid gland. Exposure of a variety of
cancer cells to a selective COX-2 inhibitor induces
apoptosis [33]. A previous study has indicated that
COX-2-derived eicosanoid products can induce Bcl-2
expression and inhibit programmed cell death [34].
The exact molecular mechanisms remain to be eluci-
dated by a further genome-wide analysis.
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Conclusions
Our results suggest that COX-2 and Bcl-2 may play
important synergistic roles in the oncogenesis, devel-
opment and metastasis of PFTC. We conclude that
COX-2 and Bcl-2 may potentially be useful prognostic
markers for PFTC. Future analysis of the role of these
markers in the prognosis of PFTC is warranted, and
should be based on larger cohorts of the tumors. The
inhibition of COX-2 activity may have an important
therapeutic benefit in the management of PFTC.
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